Showing 3671-3680 of 4164 results for "".
- TopiVert Announces Publication of Data from its Positive Phase 2 Study of TOP1630 in Dry Eye Diseasehttps://modernod.com/news/topivert-announces-publication-of-data-from-its-positive-phase-2-study-of-top1630-in-dry-eye-disease/2476303/TopiVert Pharma, a clinical-stage biotechnology company developing non-systemic kinase inhibitors (NSKIs) as novel, locally-acting medicines for the treatment of chronic inflammatory ocular diseases, announces the publication of the
- ProQR Announces Publication of QR-110 Data for Leber’s Congenital Amaurosis 10https://modernod.com/news/proqr-announces-publication-of-qr-110-data-for-lebers-congenital-amaurosis-10/2479608/ProQR Therapeutics announced the publication of a peer-reviewed manuscript describing the previously announced interim results of a clinical trial of QR-110 for the treatment of Leber’s congenital amaurosis 10 (LCA10) in the journal
- Glasses May Boost Productivity for Rural Workershttps://modernod.com/news/glasses-may-boost-productivity-for-rural-workers/2479941/Providing reading glasses may be an inexpensive way to improve productivity, as well as earnings and quality of life, among workers in developing countries, suggests a clinical trial involving tea pickers in India, according to a Reuters Health
- Eyenovia’s EYN PG21 Trial Evaluating High-Precision Microdose of Latanoprost Demonstrates IOP Lowering and Patient Usabilityhttps://modernod.com/news/eyenovias-eyn-pg21-trial-evaluating-high-precision-microdose-of-latanoprost-demonstrates-iop-lowering-and-patient-usability/2479947/Eyenovia announced positive results of its EYN PG21 proof-of-concept study of microdose latanoprost for the lowering of IOP and patient usability. The EYN PG21 clinical study investigated the medication administration effectiveness and IOP lowering effect of
- Unsafe Ocular Stem Cell Treatments Prevalenthttps://modernod.com/news/unsafe-ocular-stem-cell-treatments-prevalent/2479976/Experimental stem cell therapies for eye conditions are being offered at dozens of unregulated clinics in the United States, and some of these procedures are harmful, researchers report. Clinicians should warn their patients against
- Avedro Announces Enrollment of First Patient in Phase 3 Epi-On Corneal Cross-Linking Trialhttps://modernod.com/news/avedro-announces-enrollment-of-first-patient-in-phase-3-epi-on-corneal-cross-linking-trial/2480082/Avedro announced that it has begun enrolling patients in a pivotal phase 3 clinical trial to evaluate the safety and efficacy of an epithelium-on corneal collagen cross-linking procedure to treat patients with progres
- Foundation Fighting Blindness Launches the Stargardt Disease Natural History Studyhttps://modernod.com/news/foundation-fighting-blindness-launches-the-stargardt-disease-natural-history-study/2480086/More than 60 leading retinal disease clinical researchers from around the world gathered in Baltimore on June 11, 2018 to discuss findings from ProgStar, the Stargardt disease natural history study launched by the Foundation Fighting
- Avedro Announces $25 Million in Funding to Fuel Innovation and Commercial Growthhttps://modernod.com/news/avedro-announces-25-million-in-funding-to-fuel-innovation-and-commercial-growth/2480188/Avedro announced that it has secured $25 million in financing to invest in product development, clinical studies and commercial efforts, including expansion of sales and reimbursement support. “Avedro’s mission is to develop noninvasive corneal remodeling treatments that protect and improv
- Dark Adaptation Testing with AdaptDx Selected for Functional Assessment in Large EU Studyhttps://modernod.com/news/dark-adaptation-testing-with-adaptdx-selected-for-functional-assessment-in-large-eu-study/2480239/MacuLogix announced that the AdaptDx has been selected as a functional testing device for candidate clinical endpoint development in the MACUSTAR project, a 5-year study aimed at exploring novel outcome measures for f
- Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED)https://modernod.com/news/viridian-announces-positive-data-from-ongoing-phase-12-trial-evaluating-low-dose-vrdn-001-in-patients-with-thyroid-eye-disease-ted/2481334/Viridian Therapeutics announced positive topline clinical data from the third, low dose cohort in its ongoing phase 1/2 clinical trial of VRDN-001, an anti-insulin-like growth factor 1 receptor (IGF-1R) antibody, in patients with active thyroid eye disease (TED). The company said it believes